# Keystone 65 Rx HMO, Personal Choice 65℠ Rx PPO, Select Option® Rx PDP Plans

## 2027 Step Therapy Guidelines

*This document contains important information about some of the drugs we cover in your health plan.*

At Independence Blue Cross (IBX), we try to help keep your medications as affordable as possible.

One way we do this is by asking you to use pharmacies in our network. Another way is through a process called **step therapy**.

**This document explains:**

- What step therapy is
- Which drugs it applies to
- What to do if your drug is affected

**This document was last updated on 10/23/2026. For the most up-to-date information, or if you have questions, we're here to help:**

- **Keystone 65 Rx**: 1-844-352-1699
- **Personal Choice 65 Rx**: 1-888-879-4293
- **Select Option Rx**: 1-888-678-7009
- **TTY/TDD**: 711

You can call **seven days a week, 8 a.m. to 8 p.m.** From April 1 through September 30, calls on weekends and holidays may go to voicemail.

You can also visit **ibxmedicare.com** to search your drug list (formulary) or view and download any other plan documents.

Independence

IBX
Never stop caring

## What is step therapy?

For some health conditions, there may be more than one drug that can help. It often makes sense to start with a drug that costs less but is still safe and may work well for you.

Step therapy means:

- You may need to try **drug A** before we cover **drug B**.
- If **drug A** works for you, you can keep using it.
- If **drug A** does not work, your doctor can ask us to cover **drug B**.
- If we approve that request, we will cover **drug B**.

If you or your doctor believes that **drug A** doesn't make sense for you, you can ask us:

- To make an exception, or
- About other drugs that may work for you

You can find a list of drugs that require step therapy in this document.

You can also find more details in your plan's *Formulary* (drug list) and your *Evidence of Coverage*.

## How to use this document

Find your drug in the index on page **23**. Then read all the information listed for that drug.

If your drug has "ST" in the "Requirements" column of your health plan's drug formulary, you can find more details in this document.

## In this document:

- "We," "us," and "our" mean Independence Blue Cross.
- "Plan" and "our plan" mean Keystone 65 Rx, Personal Choice 65 Rx, or Select Option Rx.

Independence Blue Cross offers PPO, HMO-POS, and HMO Medicare Advantage plans with a Medicare contract. Enrollment in Independence Blue Cross PPO, HMO-POS, and HMO Medicare Advantage plans depends on contract renewal. Select Option is a PDP plan with a Medicare contract. Enrollment in Select Option PDP depends on contract renewal.

Independence Blue Cross offers products through its subsidiaries and affiliates including Independence Assurance Company, Independence Hospital Indemnity Plan, Keystone Health Plan East, and QCC Insurance Company — independent licensees of the Blue Cross and Blue Shield Association.

Independence

IBX
Never stop caring

4495050 (09/26)
Group 5-tier closed IBX16996 (04/26)

# AMPYRA 2027

**Products Affected**

- AMPYRA TABLET EXTENDED RELEASE 12 HOUR 10 MG ORAL

| Details | |
|---|---|
| **Criteria** | Trial of formulary generic dalfampridine. Always applies. |

# ANTIDEPRESSANTS [SNRIS] 2027

**Products Affected**

- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 20 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 40 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 80 MG ORAL
- FETZIMA TITRATION CAPSULE ER 24 HOUR THERAPY PACK 20 & 40 MG ORAL

| Details | |
|---|---|
| **Criteria** | Trial of two of the following generic formulary serotonin-norepinephrine reuptake Inhibitor (SNRI): desvenlafaxine tablet, duloxetine capsules, venlafaxine hydrochloride ER tablets, venlafaxine hydrochloride immediate release tablets, and venlafaxine hydrochloride ER capsules. Applies to new starts. |

# BRAND ANTIPSYCHOTICS 2027

**Products Affected**

- FANAPT TABLET 1 MG ORAL
- FANAPT TABLET 10 MG ORAL
- FANAPT TABLET 12 MG ORAL
- FANAPT TABLET 2 MG ORAL
- FANAPT TABLET 4 MG ORAL
- FANAPT TABLET 6 MG ORAL
- FANAPT TABLET 8 MG ORAL
- FANAPT TITRATION PACK A TABLET 1 & 2 & 4 & 6 MG ORAL
- FANAPT TITRATION PACK B TABLET 1 & 2 & 6 & 8 MG ORAL
- FANAPT TITRATION PACK C TABLET 1 & 2 & 6 MG ORAL
- LYBALVI TABLET 10-10 MG ORAL
- LYBALVI TABLET 15-10 MG ORAL
- LYBALVI TABLET 20-10 MG ORAL
- LYBALVI TABLET 5-10 MG ORAL
- SECUADO PATCH 24 HOUR 3.8 MG/24HR TRANSDERMAL
- SECUADO PATCH 24 HOUR 5.7 MG/24HR TRANSDERMAL
- SECUADO PATCH 24 HOUR 7.6 MG/24HR TRANSDERMAL

| Details | |
|---|---|
| **Criteria** | Trial of two formulary generic antipsychotics : aripiprasole, asenapine, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone. Applies to new starts. |

# BRAND BUPROPION PRODUCTS 2027

**Products Affected**

- WELLBUTRIN XL TABLET EXTENDED RELEASE 24 HOUR 150 MG ORAL
- WELLBUTRIN XL TABLET EXTENDED RELEASE 24 HOUR 300 MG ORAL

| Details | |
|---|---|
| **Criteria** | Trial of one formulary generic bupropion tablet . Applies to new starts. |

# CITALOPRAM CAPSULE 2027

**Products Affected**

- *citalopram hydrobromide capsule 30 mg oral*

| Details | |
|---|---|
| **Criteria** | Trial of generic formulary citalopram tablet and one of the following generic formulary selective serotonin reuptake inhibitors (SSRI): escitalopram tablets, fluoxetine, fluvoxamine immediate release tablets, paroxetine tablets, and sertraline tablets. Applies to new starts. |

# DRIZALMA 2027

**Products Affected**

- DRIZALMA SPRINKLE CAPSULE DELAYED RELEASE SPRINKLE 20 MG ORAL
- DRIZALMA SPRINKLE CAPSULE DELAYED RELEASE SPRINKLE 30 MG ORAL
- DRIZALMA SPRINKLE CAPSULE DELAYED RELEASE SPRINKLE 40 MG ORAL
- DRIZALMA SPRINKLE CAPSULE DELAYED RELEASE SPRINKLE 60 MG ORAL

| Details | |
|---|---|
| **Criteria** | Trial of generic formulary duloxetine. Applies to new starts. |

# DYMISTA 2027

**Products Affected**

- *azelastine-fluticasone suspension 137-50 mcg/act nasal*

| Details | |
|---|---|
| **Criteria** | Trial of both formulary generic fluticasone nasal spray and formulary generic azelastine nasal spray. Always applies. |

# EXXUA 2027

**Products Affected**

- EXXUA TABLET EXTENDED RELEASE 24 HOUR 18.2 MG ORAL
- EXXUA TABLET EXTENDED RELEASE 24 HOUR 36.3 MG ORAL
- EXXUA TABLET EXTENDED RELEASE 24 HOUR 54.5 MG ORAL
- EXXUA TABLET EXTENDED RELEASE 24 HOUR 72.6 MG ORAL
- EXXUA TITRATION PACK TABLET EXTENDED RELEASE 24 HOUR 18.2 MG ORAL

| Details | |
|---|---|
| **Criteria** | Trial of two of the following formulary generics: bupropion, citalopram tablets, desvenlafaxine extended-release (ER), duloxetine capsules, escitalopram tablets, fluoxetine, mirtazepine tablet, paroxetine IR/ER, sertraline tablets, venlafaxine IR/ER. Applies to new starts. |

# FEBUXOSTAT 2027

**Products Affected**

- *febuxostat tablet 40 mg oral*
- *febuxostat tablet 80 mg oral*

| Details | |
|---|---|
| **Criteria** | Trial of generic formulary allopurinol 100mg or 300mg. Always applies. |

# INSULIN GLARGINE 2027

**Products Affected**

- BASAGLAR KWIKPEN SOLUTION PEN-INJECTOR 100 UNIT/ML SUBCUTANEOUS

| Details | |
|---|---|
| **Criteria** | Trial of two of the following: Lantus, Toujeo,. Always applies. |

# LONG ACTING GROWTH FACTOR 2027

**Products Affected**

- FULPHILA SOLUTION PREFILLED SYRINGE 6 MG/0.6ML SUBCUTANEOUS
- ZIEXTENZO SOLUTION PREFILLED SYRINGE 6 MG/0.6ML SUBCUTANEOUS

| Details | |
|---|---|
| **Criteria** | Trial of two of the following: Neulasta, Udenyca. Always applies. |

# MULTIPLE SCLEROSIS AGENTS 2027

**Products Affected**

- COPAXONE SOLUTION PREFILLED SYRINGE 20 MG/ML SUBCUTANEOUS
- COPAXONE SOLUTION PREFILLED SYRINGE 40 MG/ML SUBCUTANEOUS
- KESIMPTA SOLUTION AUTO-INJECTOR 20 MG/0.4ML SUBCUTANEOUS
- VUMERITY CAPSULE DELAYED RELEASE 231 MG ORAL

| Details | |
|---|---|
| **Criteria** | Trial of two of the following formulary products: (1) Betaseron (interferon beta-1b), (2) Glatopa (glatiramer acetate), (3) Tecfidera (Dimethyl Fumarate), (4) Gilenya (fingolimod), (5) Teriflunomide. Applies to new starts. |

# PROTON PUMP INHIBITORS (PPIs) 2027

**Products Affected**

- *rabeprazole sodium tablet delayed release 20 mg oral*

| Details | |
|---|---|
| **Criteria** | Trial of two generic formulary proton pump inhibitors: esomeprazole capsule, lansoprazole capsule, omeprazole capsule, pantoprazole tablet . Always applies. |

# SANCUSO 2027

**Products Affected**

- SANCUSO PATCH 3.1 MG/24HR TRANSDERMAL

| Details | |
|---|---|
| **Criteria** | Trial of one formulary generic ondansetron or granisetron and one formulary generic aprepitant. Always applies. |

# SAVELLA 2027

**Products Affected**

- *milnacipran hcl tablet 100 mg oral*
- *milnacipran hcl tablet 12.5 mg oral*
- *milnacipran hcl tablet 25 mg oral*
- *milnacipran hcl tablet 50 mg oral*
- SAVELLA TABLET 100 MG ORAL
- SAVELLA TABLET 12.5 MG ORAL
- SAVELLA TABLET 25 MG ORAL
- SAVELLA TABLET 50 MG ORAL

| Details | |
|---|---|
| **Criteria** | Trial of generic formulary duloxetine. Applies to new starts. |

# SERTRALINE CAPSULE 2027

**Products Affected**

- *sertraline hcl capsule 150 mg oral*
- *sertraline hcl capsule 200 mg oral*

| Details | |
|---|---|
| **Criteria** | UNDER CMS REVIEW |

# TRULANCE 2027

**Products Affected**

- TRULANCE TABLET 3 MG ORAL

| Details | |
|---|---|
| **Criteria** | Trial of both of the following: (1) lactulose and (2) Linzess or lubiprostone. Always applies. |

# XCOPRI 2027

**Products Affected**

- XCOPRI (250 MG DAILY DOSE) TABLET THERAPY PACK 100 & 150 MG ORAL
- XCOPRI (350 MG DAILY DOSE) TABLET THERAPY PACK 150 & 200 MG ORAL
- XCOPRI TABLET 100 MG ORAL
- XCOPRI TABLET 150 MG ORAL
- XCOPRI TABLET 200 MG ORAL
- XCOPRI TABLET 25 MG ORAL
- XCOPRI TABLET 50 MG ORAL
- XCOPRI TABLET THERAPY PACK 14 X 12.5 MG & 14 X 25 MG ORAL
- XCOPRI TABLET THERAPY PACK 14 X 150 MG & 14 X200 MG ORAL
- XCOPRI TABLET THERAPY PACK 14 X 50 MG & 14 X100 MG ORAL

| Details | |
|---|---|
| **Criteria** | UNDER CMS REVIEW |

# ZONISADE 2027

**Products Affected**

- ZONISADE SUSPENSION 100 MG/5ML ORAL

| Details | |
|---|---|
| **Criteria** | Trial of generic zonisamide capsule. Applies to new starts. |

**Index**


AMPYRA TABLET EXTENDED RELEASE 12 HOUR 10 MG ORAL ..... 3
*azelastine-fluticasone suspension 137-50 mcg/act nasal* ..... 9
BASAGLAR KWIKPEN SOLUTION PEN-INJECTOR 100 UNIT/ML SUBCUTANEOUS ..... 12
*citalopram hydrobromide capsule 30 mg oral* ..... 7
COPAXONE SOLUTION PREFILLED SYRINGE 20 MG/ML SUBCUTANEOUS ..... 14
COPAXONE SOLUTION PREFILLED SYRINGE 40 MG/ML SUBCUTANEOUS ..... 14
DRIZALMA SPRINKLE CAPSULE DELAYED RELEASE SPRINKLE 20 MG ORAL ..... 8
DRIZALMA SPRINKLE CAPSULE DELAYED RELEASE SPRINKLE 30 MG ORAL ..... 8
DRIZALMA SPRINKLE CAPSULE DELAYED RELEASE SPRINKLE 40 MG ORAL ..... 8
DRIZALMA SPRINKLE CAPSULE DELAYED RELEASE SPRINKLE 60 MG ORAL ..... 8
EXXUA TABLET EXTENDED RELEASE 24 HOUR 18.2 MG ORAL ..... 10
EXXUA TABLET EXTENDED RELEASE 24 HOUR 36.3 MG ORAL ..... 10
EXXUA TABLET EXTENDED RELEASE 24 HOUR 54.5 MG ORAL ..... 10
EXXUA TABLET EXTENDED RELEASE 24 HOUR 72.6 MG ORAL ..... 10
EXXUA TITRATION PACK TABLET EXTENDED RELEASE 24 HOUR 18.2 MG ORAL ..... 10
FANAPT TABLET 1 MG ORAL ..... 5
FANAPT TABLET 10 MG ORAL ..... 5
FANAPT TABLET 12 MG ORAL ..... 5
FANAPT TABLET 2 MG ORAL ..... 5
FANAPT TABLET 4 MG ORAL ..... 5
FANAPT TABLET 6 MG ORAL ..... 5
FANAPT TABLET 8 MG ORAL ..... 5
FANAPT TITRATION PACK A TABLET 1 & 2 & 4 & 6 MG ORAL ..... 5
FANAPT TITRATION PACK B TABLET 1 & 2 & 6 & 8 MG ORAL ..... 5
FANAPT TITRATION PACK C TABLET 1 & 2 & 6 MG ORAL ..... 5
*febuxostat tablet 40 mg oral* ..... 11
*febuxostat tablet 80 mg oral* ..... 11
FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG ORAL ..... 4
FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 20 MG ORAL ..... 4
FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 40 MG ORAL ..... 4
FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 80 MG ORAL ..... 4
FETZIMA TITRATION CAPSULE ER 24 HOUR THERAPY PACK 20 & 40 MG ORAL ..... 4
FULPHILA SOLUTION PREFILLED SYRINGE 6 MG/0.6ML SUBCUTANEOUS ..... 13
KESIMPTA SOLUTION AUTO-INJECTOR 20 MG/0.4ML SUBCUTANEOUS ..... 14
LYBALVI TABLET 10-10 MG ORAL ..... 5
LYBALVI TABLET 15-10 MG ORAL ..... 5
LYBALVI TABLET 20-10 MG ORAL ..... 5
LYBALVI TABLET 5-10 MG ORAL ..... 5
*milnacipran hcl tablet 100 mg oral* ..... 17
*milnacipran hcl tablet 12.5 mg oral* ..... 17
*milnacipran hcl tablet 25 mg oral* ..... 17
*milnacipran hcl tablet 50 mg oral* ..... 17
*rabeprazole sodium tablet delayed release 20 mg oral* ..... 15
SANCUSO PATCH 3.1 MG/24HR TRANSDERMAL ..... 16
SAVELLA TABLET 100 MG ORAL ..... 17
SAVELLA TABLET 12.5 MG ORAL ..... 17
SAVELLA TABLET 25 MG ORAL ..... 17
SAVELLA TABLET 50 MG ORAL ..... 17
SECUADO PATCH 24 HOUR 3.8 MG/24HR TRANSDERMAL ..... 5
SECUADO PATCH 24 HOUR 5.7 MG/24HR TRANSDERMAL ..... 5
SECUADO PATCH 24 HOUR 7.6 MG/24HR TRANSDERMAL ..... 5
*sertraline hcl capsule 150 mg oral* ..... 18
*sertraline hcl capsule 200 mg oral* ..... 18
TRULANCE TABLET 3 MG ORAL ..... 19
VUMERITY CAPSULE DELAYED RELEASE 231 MG ORAL ..... 14
WELLBUTRIN XL TABLET EXTENDED RELEASE 24 HOUR 150 MG ORAL ..... 6
WELLBUTRIN XL TABLET EXTENDED RELEASE 24 HOUR 300 MG ORAL ..... 6
XCOPRI (250 MG DAILY DOSE) TABLET THERAPY PACK 100 & 150 MG ORAL ..... 20

XCOPRI (350 MG DAILY DOSE) TABLET THERAPY PACK 150 & 200 MG ORAL ..... 20
XCOPRI TABLET 100 MG ORAL ..... 20
XCOPRI TABLET 150 MG ORAL ..... 20
XCOPRI TABLET 200 MG ORAL ..... 20
XCOPRI TABLET 25 MG ORAL ..... 20
XCOPRI TABLET 50 MG ORAL ..... 20
XCOPRI TABLET THERAPY PACK 14 X 12.5 MG & 14 X 25 MG ORAL ..... 20
XCOPRI TABLET THERAPY PACK 14 X 150 MG & 14 X200 MG ORAL ..... 20
XCOPRI TABLET THERAPY PACK 14 X 50 MG & 14 X100 MG ORAL ..... 20
ZIEXTENZO SOLUTION PREFILLED SYRINGE 6 MG/0.6ML SUBCUTANEOUS ..... 13
ZONISADE SUSPENSION 100 MG/5ML ORAL ..... 21